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The influence of fractionated radiation therapy on plasma
vascular endothelial growth factor (VEGF) concentration in dogs
with spontaneous tumors and its impact on outcome
Abstract
BACK GROUND AND PURPOSE: Vascular endothelial growth factor (VEGF), a specific
pro-angiogenic factor is proposed to be involved in cancer progression and resistance to radiation
therapy by promoting angiogenesis and by protecting endothelial cells from radiation induced apoptosis.
The aim of this study, was first to assess the influence of ionizing radiation on plasma VEGF
concentration in spontaneous canine tumors during fractionated radiation therapy with curative or
palliative intent and second to analyze plasma VEGF concentration as predictor for treatment outcome.
PATIENTS AND METHODS: For plasma VEGF analysis a human VEGF enzyme linked
immunosorbent assay was used. Sixty dogs with various tumor types were included in this study. Dogs
were irradiated with either low dose per fx (3-3.5 Gy per fraction, total dose: 42-49 Gy, group A:
curative intent) or high dose per fx (6-8 Gy per fraction, total dose: 24-30 Gy, group B: palliative
intent). Blood samples were taken before and after dose application at certain time points during
therapy. Follow-up evaluation was performed for analysis of time to treatment failure and survival.
RESULTS: Repeated measures analysis showed no increase of plasma VEGF in dogs treated with
fractionated radiation therapy (group A and B). Dichotomizing baseline plasma VEGF into two groups
with high and low plasma VEGF, resulted in shorter time to treatment failure in dogs with high plasma
VEGF levels (TTF, group A: P=0.038, group B: P=0.041). CONCLUSIONS: This study demonstrated
that dogs with a plasma VEGF level higher than 5 pg/ml had a poorer outcome after radiation therapy. It
is therefore, suggested, to use plasma VEGF as predictor for treatment outcome in radiation therapy.
Radiotherapy and Oncology 79 (2006) 239–244
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Abstract
Back ground and purpose: Vascular endothelial growth factor (VEGF), a specific pro-angiogenic factor is proposed to be
involved in cancer progression and resistance to radiation therapy by promoting angiogenesis and by protecting
endothelial cells from radiation induced apoptosis. The aim of this study, was first to assess the influence of ionizing
radiation on plasma VEGF concentration in spontaneous canine tumors during fractionated radiation therapy with
curative or palliative intent and second to analyze plasma VEGF concentration as predictor for treatment outcome.
Patients and methods: For plasma VEGF analysis a human VEGF enzyme linked immunosorbent assay was used. Sixty
dogs with various tumor types were included in this study. Dogs were irradiated with either low dose per fx (3–3.5 Gy per
fraction, total dose: 42–49 Gy, group A: curative intent) or high dose per fx (6–8 Gy per fraction, total dose: 24–30 Gy,
group B: palliative intent). Blood samples were taken before and after dose application at certain time points during
therapy. Follow-up evaluation was performed for analysis of time to treatment failure and survival.
Results: Repeated measures analysis showed no increase of plasma VEGF in dogs treated with fractionated radiation
therapy (group A and B). Dichotomizing baseline plasma VEGF into two groups with high and low plasma VEGF, resulted in
shorter time to treatment failure in dogs with high plasma VEGF levels (TTF, group A: PZ0.038, group B: PZ0.041).
Conclusions: This study demonstrated that dogs with a plasma VEGF level higher than 5 pg/ml had a poorer outcome
after radiation therapy. It is therefore, suggested, to use plasma VEGF as predictor for treatment outcome in radiation
therapy.
q 2006 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 79 (2006) 239–244.
Keywords: Canine; Plasma VEGF; Time to treatment failure; Survival; RadiationTumor angiogenesis is an important factor in disease
progression and formation of metastasis [12]. One major
pro-angiogenic factor is vascular endothelial growth factor
(VEGF). VEGF promotes tumor angiogenesis, endothelial
cell survival and vessel maintenance of immature vessels
[12,13]. VEGF is involved in development and growth of a
wide variety of different tumors [15,17]. VEGF is actively
secreted from tumor cells and its soluble form (VEGF165) is
detectable in the blood compartment [9].
Exposure of tumor cells to ionizing radiation can increase
VEGF mRNA [2] and protein concentration [14]. Ionizing
radiation can lead to phosphorylation of the PI-3kinase via
the epidermal growth factor receptor (EGFR) in tumor cells.
This is the first step in activating the ERK pathway, a
mitogen activated protein kinase (MAPK) pathway. This
pathway is mediating cell survival and upregulation of VEGF0167-8140/$ - see front matter q 2006 Elsevier Ireland Ltd. All rights reseexpression in tumor cells [4,9]. In human squamous
carcinoma cells the activation was dependent on the
radiation dose, with low doses (1 Gy) causing prolonged
activation of the ERK pathway and higher doses (6 Gy)
having a weaker activation [4].
Cells incubated under hypoxic conditions had increased
VEGF expression [22,25]. This increase was mediated by the
hypoxia inducible factor-1 (HIF-1). HIF-1 consists of two
subunits, HIF-1a and HIF-1b. Under normoxic conditions HIF-
1a is rapidly degraded [22,25], but in hypoxic cells the
heterodimer HIF-1 can bind to DNA at specific regions, called
hypoxia responsive elements (HRES) which includes a 28-bp
element that is sufficient to mediate upregulation of VEGF
transcription [19]. Several studies have associated HIF-1
expression with human cancer progression, such as head and
neck cancer, ovarian cancer and esophageal cancer [11,33].rved. doi:10.1016/j.radonc.2006.03.021
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elevated systemic levels of VEGF in head and neck cancer has
been shown [3]. In dogs with spontaneous tumors low
hemoglobin levels correlated with high plasma VEGF levels
[27]. In this study, a significant difference of plasma VEGF
concentration in different tumor types was found with high
levels in carcinoma, osteosarcoma, and melanoma [27].
Low pre-operative serum VEGF levels (!575 pg/ml) were
shown to correlate with increased disease free survival, in
human patients with colorectal cancer indicating that serum
VEGF was a good predictor for outcome [29]. When serum
and plasma VEGF in patients with primary colorectal
carcinoma were analyzed separately, both, high serum and
high plasma VEGF concentrations predicted for shorter
survival, but significance was only reached for serum VEGF
values [29]. In contrast, high plasma VEGF was shown to be a
significant predictor of reduced overall survival and of
earlier onset of local recurrence for patients with breast
cancer [23,30].
Therefore, we were interested whether (1) the influence
of a low dose per fx (3–3.5 Gy per fraction, total dose: 42–
49 Gy, group A: curative intent) or high dose per fx (6–8 Gy
per fraction, total dose: 24–30 Gy, group B: palliative intent)
on the VEGF release from tumor cells can be measured in
plasma of dogs with spontaneous tumors, and (2) if baseline
plasma VEGF as well as the course of plasma VEGF during
therapy can predict time to treatment failure (TTF) and
survival.Material and methods
Patient selection
Sixty tumor bearing dogs were included in this study.
There were 38 male dogs and 22 female dogs (12 neutered
male and nine neutered female dogs). The median age of
patients was 9.0 years (range 3–16 years). The study groupTable 1
Tumor related parameters and treatment response
Tumor histology Stage of disease (N)
I II III IV
Group A
Sarcoma
Fibrosarcoma 4 1 2
Osteosarcoma 1
Myxosarcoma
Carcinoma 3 3 1
Epulis 2 1
Group B
Sarcoma
Fibrosarcoma 2 1
Osteosarcoma 1 4
Sarcoma, other 2 2 4 1
Histiocytosis, malig.
Melanoma 1 1
a No response to therapy.
b Partial response.
c Complete response.included 35 pure breed dogs of various breeds and 25 mixed
breed dogs. The median weight of these dogs was 29.7 kg
(range 5.1–66 kg). The routine work up included in all
animals a complete physical exam, blood count, serum
chemistry, thoracic radiographs, biopsies of the primary
tumor using a needle punch biopsy (Tru-cut, Baxter General
Health Care, Deerfield, Illinois) or an incisional biopsy for
routine histopathological diagnosis. Fine needle aspiration
of enlarged lymph nodes was performed using a 22-gauge
needle and a 5 ml syringe. Further diagnostic work up was
done as indicated. Patients with sarcomas of soft tissue
(nZ28) or bone origin (nZ14), carcinomas (nZ9), oral
melanomas (nZ6) and three dogs with acanthomatous epulis
were included (Table 1). All patients were staged based on
the world health organization (WHO) system [24] (Table 1).
For 17 patients no staging system was applicable. The
length, width and depth of tumors were measured and the
volume was calculated using the rotation ellipsoid formula
(pabc/6). The median tumor volume was 35.7 cm3 (range
0.1–392.5 cm3). The initial tumor response at the end of
fractionated radiation therapy was defined as no response
(unchanged tumor volume), partial response (decreased
tumor volume), or complete response (no macroscopic
tumor disease) (Table 1). Acute side effects of normal tissue
were recorded by using the toxicity criteria suggested by the
VRTOG [18]. Informed consent of owners was obtained.Anesthesia protocol
All dogs were anesthetized for radiation therapy.
Midazolam (Dormicumw, Roche Pharma AG, Reinach,
Switzerland) was injected at a dosage of 0.125 mg/kg
intravenously immediately followed by propofol (Propofolw,
Fresenius Kabi AG, Stans, Switzerland), slowly administered
to effect. Anesthesia was maintained after intubation with
isoflurane and oxygen (Forenew, Abott AG, Baar, Switzer-
land). During anesthesia dogs were monitored with pulse
oxymetry and ECG.Tumour response Plasma VEGF
(pg/ml)
N (total)
NRa PRb CRc
2 4 1 4.7 7
1 12.2 1
1 0.0 1
3 1 4 11.7 9
3 3.2 3
2 1 2.8 3
7 6 9.8 14
4 4 1 4.5 12
1 2 1 0.8 4
1 2 2 12.5 6
M.C. Wergin et al. / Radiotherapy and Oncology 79 (2006) 239–244 241Treatment regimens
All dogs were treated with radiation therapy. The
treatment was chosen based on tumor volume, tumor
stage, tumor histology and overall health of the dog. To be
included all dogs had to have a measurable tumor mass.
Radiation therapy was given with a linear accelerator (BBC
Dinary 20) using 6 MV photons or 5- to 16-MeV electrons. If
indicated, computer treatment planning was performed
with CadPlan 6.0. A total of 21 dogs (group A) were
irradiated with a low dose per fraction (fx) with a total
dose of 42–49 Gy (curative intent). Dogs were treated either
with 3.5 Gy fractions on a Monday, Tuesday, Thursday and
Friday schedule or a daily fractionation scheme with 3 Gy
fractions was used. Thirty-nine dogs (group B) were treated
with a high dose per fx with a total dose of 30 Gy delivered in
five fractions, or a total dose of 24 Gy delivered in three or
four fractions (palliative intent). Detailed data are given in
Table 2.Blood samples and VEGF assay
Three milliliters of blood were collected into sterile CTAD
tubes (Beckton and Dickinson Vacutainer System, France) and
placed on ice. CTAD tubes contained sodium citrate,
theophyllin, adenosine and dipyridamine allowing maximal
platelet stabilization. The tubes were centrifuged within
15 min at 2500!g for 30 min at 4 8C [31]. The resulting plasma
was separated and stored immediately at K80 8C. The
technique of blood sampling and handling of probes has been
published previously [10,31]. Thrombocyte count in CTAD
plasma was measured and the amount was at the detection
limit (!5000). A blood sample, taken before therapy, served
as baseline plasma VEGF. In group A, blood samples were
always taken before the 1st and after the 3rd, 6th, 8th, 10th,
12th and 14th fraction. Blood samples were obtained before
the 1st and after every following fraction in group B.
VEGF concentration was determined by using the Human
VEGF enzyme linked immunosorbent assay (ELISA, R&D
System, Inc., Abingdon, United Kingdom) designed for
detection of VEGF165. This ELISA has already been proven
reliable for plasma VEGF evaluations in dogs in recent
studies [6,7,27]. The VEGF ELISA was accomplished using the
protocol from the manufacturer. The standard curve wasTable 2
Fractionation scheme for curative (group A) and palliative (group
B) treatment
Dose per
fx (Gy)
Fx per
week
Total fx Total dose (Gy) Dogs (N)
Group Aa
3.5 4 12 42 3
3.5 4 14 49 11
3.0 5 14 49 4
3.0 5 16 52 3
Group Bb
6.0 2 5 30 25
6.0 1 4 24 8
8.0 1 3 24 6
a Dogs receiving a low dose per fx, with a high total dose.
b Dogs receiving a high dose per fx, with low total dose.adapted for low concentrations and the detection limit was
tested up to 1 pg/ml. A standard curve was assayed for each
microtiter plate. After thawing, every aliquot was assayed
twice and the mean value was taken for statistical analysis.
Inter- and intra-donor variations have been tested in healthy
dogs [28].
Outcome measures
Time to treatment failure (TTF) was defined to be the
interval from the date of completion of radiation therapy to
the date of disease recurrence or progression and/or the
observation of metastasis. The survival time was defined as
the time interval from start of therapy to death/euthanasia.
Follow-up evaluation was performed in our clinic or by the
referring veterinarian 3 and 6 months after completion of
therapy and then every year thereafter.
Statistical analysis
Plasma VEGF levels showed a skewed distribution,
therefore plasma VEGF levels were transformed logarithmi-
cally before analysis (plasma ln VEGF). Statistical analysis
(StatView Version 4.0 statistical software application,
Abacus concept) was performed using the descriptive
statistics and for correlation of plasma VEGF and tumor
response the Kruskal–Wallis test was used. Estimates of
probabilities for time to treatment failure (TTF) were
calculated by the Kaplan–Meier method, and differences
between groups were tested with the log rank statistic. The
plasma VEGF concentration was scored as low if plasma VEGF
was less than the 50th percentile of baseline plasma VEGF of
all tumor bearing dogs. The median plasma VEGF for all dogs
was 5.2 pg/ml. Therefore, groups were dichotomized in
patients having a plasma VEGF concentration lower or higher
5 pg/ml. To analyze the effect of ionizing radiation on VEGF
release over time the repeated measures analysis with
Greenhouse–Geisser correction was used (SPSS program).
This test was distinguished from MANOVA to test within
subject effects. For this analysis plasma VEGF levels after
dose application were subtracted from baseline plasma
VEGF. P values%0.05 were considered significant.Results
Baseline analysis
Dogs receiving a low dose per fx, high total dose
(group A)
Median plasma VEGF was 6.2 pg/ml. Dogs having no
response (NR) to radiation therapy had median plasma VEGF
of 10.1 pg/ml, dogs with a partial response (PR) had median
plasma VEGF of 7.5 pg/ml and dogs with a complete
response (CR) had median plasma VEGF of 5.7 pg/ml. But
differences between groups were not statistically significant
(PZ0.67).
Dogs receiving a high dose per fx, low total dose
(group B)
Median plasma VEGF in this group was 4.8 pg/ml. For non-
responders the median plasma VEGF was 9.7 pg/ml, dogs
Plasma VEGF in dogs during fractionated radiation therapy242with PR had median plasma VEGF of 3.2 pg/ml and dogs
without macroscopic disease had median plasma VEGF of
0.4 pg/ml. But differences between groups were not
statistically significant (PZ0.2).
Plasma VEGF measured over the course
of radiation therapy
Dogs receiving a low dose per fx, high total dose
(group A)
Change of plasma VEGF during radiation therapy was not
statistically different (PZ0.7). Plasma VEGF during radiation
therapy in dogs with sarcomas was stable (sarcoma: PZ
0.57). The mean plasma VEGF level of dogs with carcinoma
increased slightly over the course of radiation therapy
although this was not significant (PZ0.3). Plasma VEGF
levels directly before and after dose application did not
differ. The repeated measures analysis with the covariables:
tumor volume, tumor stage and radiation reaction were
computed separately and none of the covariables influenced
plasma VEGF during therapy (tumor volume: PZ0.2, tumor
stage: PZ0.3, radiation reaction: PZ0.4).
Dogs receiving a high dose per fx, low total dose
(group B)
Plasma VEGF in dogs treated with a high dose per fraction
remained unchanged (PZ0.8). The same was seen when
patients were grouped according to tumor histology, such as
melanoma (PZ0.6), sarcoma (PZ0.5) and carcinoma (PZ
0.8). Plasma VEGF levels directly before and after dose
application did not differ. None of the covariables influenced
the course of plasma VEGF (tumor volume: PZ0.7, tumor
stage: PZ0.4, radiation reaction: PZ0.5) (Fig.1).
Treatment outcome
Comparison of dogs irradiated with a curative intent (low
dose per fx, high total dose) to dogs irradiated with a
palliative intent (high dose per fx, low total dose) resulted inFig. 1. TTF curve for dogs treated with a high total dose: Kaplan–
Meier time to treatment failure curves for baseline plasma VEGF
concentration in dogs treated with a high total dose (group A). The
median plasma VEGF for all dogs was 5.2 pg/ml. Therefore, groups
were dichotomized in patients having a plasma VEGF concentration
lower or higher 5 pg/ml. Dogs with a plasma VEGF level higher
5 pg/ml had a significantly shorter TTF (PZ0.038).significantly longer survival in dogs irradiated with a low
dose per fraction (high total dose) (data not shown).
Therefore, the survival analysis was computed for both
groups separately. Dogs remaining alive at last follow-up or
dogs that died of unrelated reasons were censored.Dogs receiving a low dose per fx, high total dose
(group A)
The median follow-up time was 524 days (mean:
490 days). At the time of analysis 14 out of 21 dogs had
died because of their cancer disease. Seven dogs were
censored, five dogs were still alive at the time of analysis and
two dogs died of unrelated reasons. The median TTF of the
14 dogs was 153 days (31–440 days). When baseline plasma
VEGF was dichotomized into two groups with plasma VEGF
levels of %5 pg/ml (nZ7), respectively O5 pg/ml (nZ7),
then dogs with a plasma VEGF level higher 5 pg/ml had a
significantly shorter TTF (PZ0.04) (Fig. 2). The median TTF
of dogs with a plasma VEGF%5 pg/ml was 243 days and for
dogs with plasma VEGF O5 pg/ml the median TTF was
136 days. This difference in pretreatment plasma VEGF also
resulted in a shorter survival time (PZ0.04).
Further, we looked at the course of plasma VEGF during
radiation therapy and its influence on TTF and survival. Dogs
were separated into two groups. One group had increasing
the other had decreasing or unchanged plasma VEGF levels.
However, TTF and survival were not influenced by increasing
or decreasing plasma VEGF levels.Dogs receiving a high dose per fx, low total dose
(group B)
The median follow-up time was 93 days (mean: 125 days).
Out of 39 dogs, 10 dogs were censored, of which three were
still alive at the time of analysis, five dogs died of unrelated
causes and two dogs were lost to follow-up. Dogs with high
plasma VEGF (O5 pg/ml) had a significant shorter TTF (PZ
0.04) (Fig. 2). The median TTF for dogs with plasma VEGF
%5 pg/ml (nZ14) was 102 days and dogs with O5 pg/mlFig. 2. TTF curve for dogs treated with a low total dose: Kaplan–
Meier time to treatment failure curves for baseline plasma VEGF
concentration in dogs treated with a low total dose (group B). The
median plasma VEGF for all dogs was 5.2 pg/ml. Therefore, groups
were dichotomized in patients having a plasma VEGF concentration
lower or higher 5 pg/ml. Dogs with a plasma VEGF level higher
5 pg/ml had a significantly shorter TTF (PZ0.041).
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difference in pretreatment plasma VEGF also resulted in a
shorter survival time (PZ0.03). The course of plasma VEGF,
as mentioned above, was not influencing TTF or survival.
Dogs that responded to therapy and had a plasma VEGF level
%5 pg/ml had a significantly longer TTF (PZ0.004) and
longer life span (PZ0.005).Discussion
VEGF is known to protect endothelial cells for radiation
induced apoptosis [21,26,32]. Therefore, we were inter-
ested in changes of plasma VEGF during fractionated
radiation therapy with either high or low dose per fraction.
However, our study did not reveal a significant increase of
plasma VEGF during fractionated radiation therapy in both
treatment groups. In vitro, a 2.5-fold increased VEGF
concentration has been measured in lung squamous carci-
noma cells exposed to a single fraction of 15 Gy [2]. This
increase was measurable up to 24 h and it was dependent on
the activation of the ERK cascade through activation of the
EGFR [2,9]. The activation of the ERK pathway was dose
dependent with increased activity after exposure to a low
radiation dose (1 Gy) [4]. Interestingly, we found that dogs
with carcinoma irradiated with a low dose per fraction had a
slight increase of plasma VEGF, although this was not
significant.
The regulatory mechanism of VEGF expression is not only
dependent on the activation of ERK. Hypoxia is also a strong
stimulus for VEGF expression in tumor cells. Recently, serial
oxygen partial pressure measurements (pO2) were done in
spontaneous canine tumors during fractionated radiation
therapy and the data suggest that tumors may behave
differently with increasing or decreasing tumor oxygen levels
during radiation therapy [1]. These findings may explain
increasing or decreasing plasma VEGF concentrations during
therapy in individual dog patients in this study. Additionally,
micro vessel density (MVD) seems to negatively correlate
with VEGF and positively correlate with tumor oxygenation
status [8]. We were able to analyse MVD in seven patients
and we found a median MVD of 3.2 vessels per visual field.
Dogs with a high plasma VEGF (O5 pg/ml, nZ2) had a
median MVD of 2.2 and dogs with a low plasma VEGF
(%5 pg/ml, nZ5) had a median MVD of 4.8. This preliminary
result might indicate that tumors with a high MVD are better
oxygenated resulting in a lower plasma VEGF. Due to small
sample size a definitive conclusion cannot be drawn.
In a previous study [28], we analyzed the course of VEGF
during fractionated radiation therapy in a smaller study
group and there was a tendency for increased plasma VEGF
level in curatively treated dogs. That this tendency did not
reach significance in this larger patient group might be due
to several factors. First, a counterbalancing effect might
occur between ERK pathway activation and changes in the
oxygenation status of the tumor. Second, the existence of
mechanisms avoiding VEGF release from tumor tissue have
been demonstrated. Possibly, binding of VEGF to its receptor
and to extracellular matrix occurs and would explain the
unchanged plasma VEGF levels. For example, after breast
cancer surgery higher VEGF levels were found in wound fluidthan in the blood compartment [16]. The lack of significant
differences in plasma VEGF levels during radiation therapy
might be the simple fact that changes were too small to be
detected.
This study demonstrated that high pre-irradiation plasma
VEGF levels in dogs with spontaneous tumors resulted in
shortened survival times. This was seen in both treatment
groups. Interestingly, this prediction was not dependent on
tumor histology or tumor stage. Additionally, we found
lowest median plasma VEGF levels in dogs with a complete
response to therapy in both treatment groups. Correspond-
ingly, palliatively treated dogs (group B) with a low plasma
VEGF level that responded to therapy had also a significantly
longer TTF and a longer live span. In a human colorectal
cancer study, it was also shown that high plasma and serum
VEGF concentration prior to surgery predicted decreased
overall survival [5,29].
In a mouse model study, it has been demonstrated that
even a minimal increase in plasma VEGF can cause growth of
micrometastasis by tipping the balance towards angiogen-
esis [20]. Therefore, we wanted to analyze if increasing
concentrations of plasma VEGF over the course of radiation
therapy in individual patients would result in shortened TTF
and survival. However, increasing plasma VEGF over time
had no effect on survival or TTF.
In conclusion, plasma VEGF appeared to be a good
prognostic indicator for dog patients receiving radiation
therapy. First, dogs with a low plasma VEGF level are more
likely to respond to radiation therapy and second these dogs
also have a longer TTF and survival.
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